** Shares of drugmaker Merck MRK.N rise 1.5% to $101.57 premarket
** MRK and Chinese biotech Hansoh Pharma 3692.HK have signed global licensing deal for experimental obesity drug, HS-10535, co says
** Hansoh to receive $112 mln upfront and $1.9 bln in milestone payments
** MRK will take $112 mln charge before taxes in Q4 2024 as part of the deal
** 21 of 28 brokerages rate the stock "buy" or higher and 7 "hold"; their median PT is $130 - LSEG
** As of last close, stock has fallen 8.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。